The apolipoprotein testing market has seen considerable growth due to a variety of factors.
• There has been a robust expansion in the apolipoprotein testing market size over the recent years. Its growth is projected to increase from $2.93 $ billion in 2024 to $3.11 $ billion in 2025, showing a compound annual growth rate (CAGR) of 6.0%.
The escalation during the past period can be credited to the rising focus on preventive healthcare, the outsourcing of diagnostic procedures, the setting of regulatory approvals and guidelines, the expanding population of elderly individuals and the swell in investment towards clinical trials.
The apolipoprotein testing market is expected to maintain its strong growth trajectory in upcoming years.
• The size of the apolipoprotein testing market is predicted to witness significant expansion in the upcoming years, rising to $3.88 billion in 2029 with a compound annual growth rate (CAGR) of 5.7%.
This expansion during the forecast period is linked to factors such as the development of healthcare infrastructure, introduction of new testing panels, a rise in cardiovascular diseases, increased awareness about obesity-related issues, and the advent of precision nutrition. The forecast period will also see prevalent trends like advancements in bioinformatics tools, gene editing technologies, improvements in sample management and storage, the merging of molecular diagnostics with telemedicine, and association with digital health platforms.
The uptick in cases of cardiovascular diseases is projected to bolster the expansion of the apolipoprotein testing market in the future. Cardiovascular diseases, a collective name for disorders affecting the heart and blood vessels, are known to trigger heart attacks, strokes, and peripheral vascular ailments. The increase in these disorders is attributed largely to unhealthy eating habits, a spike in obesity levels, and an ageing demographic. Apolipoproteins such as ApoA-I and ApoB, play a vital role in lipid transport within the blood, testing their levels can offer insights into the risk of cardiovascular disease and enable customization of lipid-lowering treatments for better management. For example, a report released by the American Heart Association, a US-based nonprofit organization committed to cardiovascular medical research, in January 2024, revealed that cardiovascular disease accounted for 931,578 deaths in the US in 2021. Moreover, in January 2023, the same organization reported that cardiovascular diseases were responsible for 928,741 deaths in 2020. Hence, the escalating prevalence of cardiovascular diseases fuels the growth of the apolipoprotein testing market.
The apolipoprotein testingmarket covered in this report is segmented –
1) By Type Of Apolipoprotein: Apolipoprotein A-I, Apolipoprotein B, Apolipoprotein E
2) By Technology: Immunoassays, Polymerase Chain Reaction (PCR)
3) By Application: Cardiovascular Disease Risk Assessment, Genetic Testing, Other Applications
4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes
Subsegment:
1) By Apolipoprotein A-I: Quantitative Testing, Qualitative Testing, Functional Testing
2) By Apolipoprotein B: Total Apolipoprotein B Testing, Apolipoprotein B100 Testing, Apolipoprotein B48 Testing
3) By Apolipoprotein E: Genotyping Tests, Protein Level Testing, Functional Assays
Leading corporations active in the apolipoprotein market are launching enhanced heart health schemes, designed to deliver more in-depth analyses and individualized advice for cholesterol management and cardiovascular disease prevention. These improved heart health schemes are essentially upgraded wellness programs that provide comprehensive appraisals and personalized counsel to optimize heart health. For instance, InsideTracker, an American personal health analytics firm, rolled out its Ultimate Plan in January 2023. This plan now includes the measurement of Apolipoprotein B (ApoB), a crucial heart health marker. This feature allows users to gain a more detailed understanding of their cardiovascular health, particularly because high ApoB levels are linked to increased probabilities of atherosclerosis and heart disease occurrence. InsideTracker's plan provides users with insights into how their ApoB levels measure up against conventional ranges as well as customized lifestyle guidance, all based on extensive research carried out by the InsideTracker science team.
Major companies operating in the apolipoprotein testing market are:
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Mayo Clinic Laboratories
• Laboratory Corporation of America Holdings
• Quest Diagnostics Incorporated
• Bio-Rad Laboratories Inc.
• Randox Laboratories Ltd.
• R&D Systems Inc.
• Elabscience Bionovation Inc.
• Sekisui Diagnostics LLC
• RayBiotech Inc.
• Mabtech AB
• Bioss Inc.
• Aviva Systems Biology Corporation
• Abnova Corporation
• DiaSys Diagnostic Systems GmbH
• Biocompare Inc.
• Enzo Life Sciences Inc.
• Eagle Biosciences Inc.
• CLOUD-CLONE CORP.
• ELK Biotechnology CO. Ltd.
• LifeSpan BioSciences Inc.
North America was the largest region in the apolipoprotein testing market in 2024. The regions covered in the apolipoprotein testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.